https://www.superiorhealthplan.com/newsroom/july-2020-new-drugs-requiring-utilization-management.htmlNews
July 2020: New Drugs Requiring Utilization Management
Date:06/30/20
Superior HealthPlan is committed to keeping providers updated on prescription drugs as they enter the market, whether or not they will need prior authorization, as well as how these drugs may be billed. Upon approval from the U.S. Food and Drug Administration (FDA) and/or availability onto the market, and if determined by Superior that the drug will be a covered benefit, these drugs will be subjected to utilization management. This can include, but is not limited to clinical prior authorization, quantity limit and age limit or specialty pharmacy.
Depending on the formulation/route of administration of the drug, the drug may be billed under the pharmacy benefit or medical benefit as a Clinician Administered Drug (CAD). CADs are billed using a Healthcare Common Procedure Coding System (HCPCS) J Code. Most CAD drugs, upon FDA approval, will not have a specific J Code assigned. Instead, they will fall under the miscellaneous J Code (J3590) until they are officially assigned their own J Code.
For July, the following drugs will be subjected to utilization management:
DRUG NAME BRAND (GENERIC) ROUTE OF ADMINISTRATION
INDICATION
1 Fensolvi (leuprolide acetate)
Subcutaneous
Central Precocious Puberty
2 Retevmo (selpercatinib)
Oral
Cancer
3 Qinlock (ripretinib)
Oral
Gastrointestinal Stromal Tumor
4 artesunate
Intravenous
Malaria
5 naxitamab
Intravenous
Cancer
6 givinostat
Oral
Duchene’s Muscular Dystrophy
7 Nyvepria (pegfilgrastim-apgf)
Subcutaneous
Neutropenia
8 Recarbrio (imipenem/cilastin/relebactam)
Intravenous
Antibiotic
9 Revascor (rexlemestrocel-L)
Intramyocardial Injection
Chronic Heart Failure
10 valoctocogene roxaparvovec
Intravenous
Hemophilia A
11 Ryoncil (remestemcel-L)
Intravenous
Acute graft vs. host disease
12 KTE-X19
Intravenous
Mantle Cell Lymphoma
13 lisocabtagene maraleucel
Intravenous
Non-Hodgkin's Lymphoma
14 oxymetazoline
Ophthalmic Solution
Blepharoptosis
15 Viaskin Peanut
Transdermal Patch
Peanut Allergy
16 veverimer
Oral
Chronic Kidney Disease (CKD)
17 Winlevi (clascoterone)
Topical
Acne
18 viloxazine
Oral
ADHD
19 cantharidin
Topical
Molluscum Contagiosum
20 Gimoti (metoclopramide)
Nasal Spray
Diabetic Gastroparesis
21 Fintelpa (fenfluramine)
Oral
Dravet Syndrome
22 Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
Subuctaneous
Breast Cancer
Please note:Some of the drugs listed above are billed under the medical benefit. To determine which of these drugs under the medical benefit will need prior authorization, please utilizeSuperior’s Pre-Auth Needed Tool.For detailed information regarding utilization management, including prior authorization criteria and quantity limits, please visitSuperior’s Pharmacy webpage. For information regarding utilization management for Ambetter from Superior HealthPlan, please referenceAmbetter’s 2020 Prescription Drug List.
For questions regarding any of the drugs listed above and utilization management or prior authorization for these drugs, please contact the Superior Pharmacy Department at 1-800-218-7453, ext. 22080.
- Forums
- ASX - By Stock
- MSB
- REVASCOR - CHF Insurance Coverage
REVASCOR - CHF Insurance Coverage, page-59
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
98.0¢ |
Change
-0.010(1.01%) |
Mkt cap ! $1.118B |
Open | High | Low | Value | Volume |
$1.00 | $1.01 | 98.0¢ | $4.720M | 4.751M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 171759 | 98.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.0¢ | 16000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 171759 | 0.980 |
6 | 123454 | 0.975 |
9 | 228392 | 0.970 |
6 | 122208 | 0.965 |
10 | 79500 | 0.960 |
Price($) | Vol. | No. |
---|---|---|
0.990 | 16000 | 1 |
0.995 | 62678 | 2 |
1.000 | 70444 | 6 |
1.005 | 27224 | 1 |
1.010 | 48336 | 6 |
Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |